Amgen (NASDAQ: AMGN) has recently announced a quarterly dividend of $2.38 per share, set to be paid on September 12, 2025. This decision reflects Amgen's ongoing commitment to returning capital to shareholders while maintaining robust operational performance. As a dividend aristocrat and a prominent player in the biotechnology sector, Amgen's dividend yield and steady payouts can appeal to both income and growth investors. Given Amgen's position as a key constituent of major indices such as the Dow Jones Industrial Average and the Nasdaq-100, the stock often attracts institutional investment, benefitting from increased liquidity. Investors should note that the biotechnology industry, characterized by rapid innovation and intense competition, carries inherent risks. Generic competition and regulatory scrutiny could impact Amgen's pricing power and market share. Specifically, the involvement in producing and marketing biosimilars presents both opportunities and challenges.